Personensuche
Personensuche
Es wurde 1 Person gefunden.
Anschrift
Hufelandstraße 55
45147 Essen
45147 Essen
Telefon
Telefax
E-Mail
Webseite
Sprechzeiten
ab 17 Uhr
Funktionen
-
Funktionsoberarzt/-ärztin, Klinik für Neurologie
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
[⁶⁸Ga]-DOTA-conjugated somatostatin receptor-targeting peptide PET for the differentiation between meningioma and glioblastoma : A case report and review of the literatureIn: Oncology Letters , Jg. 29 2025, Nr. 4, 199DOI (Open Access)
-
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccineIn: Nature Communications , Jg. 15 2024, Nr. 1, 6870DOI (Open Access)
-
KDM5B predicts temozolomide-resistant subclones in glioblastomaIn: iScience , Jg. 27 2024, Nr. 1, 108596DOI (Open Access)
-
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trialIn: Nature Communications , Jg. 15 2024, Nr. 1, 4210DOI (Open Access)
-
Predictors and surgical outcome of hemorrhagic metastatic brain malignanciesIn: Journal of Neuro-Oncology , Jg. 169 2024, Nr. 1, S. 165 – 173DOI (Open Access)
-
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma : A Comparison of Tissue, ⁶⁸Ga-FAPI-46 PET Data, and Survival DataIn: Journal of Nuclear Medicine (JNM) , Jg. 65 2024, Nr. 8, S. 1217 – 1223
-
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaIn: Clinical Cancer Research , Jg. 29 2023, Nr. 2, S. 488 – 500DOI (Open Access)
-
Are we providing best available care to newly diagnosed glioblastoma patients? : Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022In: Neuro-Oncology Advances , Jg. 5 2023, Nr. 1, vdad105DOI, Online Volltext (Open Access)
-
Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRIIn: Nuclear Medicine Communications , Jg. 44 2023, Nr. 12, S. 1106 – 1113
-
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastomaIn: Neuro-Oncology Advances , Jg. 5 2023, Nr. 1, vdad090DOI, Online Volltext (Open Access)
-
Precision neuro-oncology : A pilot analysis of personalized treatment in recurrent gliomaIn: Journal of Cancer Research and Clinical Oncology , Jg. 149 2023, Nr. 7, S. 3513 – 3526DOI (Open Access)
-
Telemedicine in Neuro-Oncology : An Evaluation of Remote Consultations during the COVID-19 PandemicIn: Cancers , Jg. 15 2023, Nr. 16, 4054DOI (Open Access)
-
Gender disparity regarding work-life balance satisfaction among German neuro-oncologists : A YoungNOA surveyIn: Neuro-Oncology , Jg. 24 2022, Nr. 9, S. 1609 – 1611DOI (Open Access)
-
Medikamentöse Therapie der häufigsten HirnmetastasenIn: Die Onkologie , Jg. 28 2022, Nr. 5, S. 389 – 394
-
Meningeosis neoplastica : Epidemiologie, Diagnostik und TherapieIn: Die Onkologie , Jg. 28 2022, Nr. 7, S. 395 – 404
-
Correction to : Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high‑grade glioma in clinical practice (Journal of Neuro-Oncology, (2020), 148, 3, (489-500), 10.1007/s11060-020-03540-6)In: Journal of Neuro-Oncology , Jg. 151 2021, Nr. 2, S. 339DOI (Open Access)
-
Demographic, radiographic, molecular and clinical characteristics of primary gliosarcoma and differences to glioblastomaIn: Clinical Neurology and Neurosurgery , Jg. 200 2021, 106348
-
How about levetiracetam in glioblastoma? An institutional experience and meta‐analysisIn: Cancers , Jg. 13 2021, Nr. 15, 3770DOI, Online Volltext (Open Access)
-
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy : Lessons learned from the CeTeG/NOA-09 trialIn: International Journal of Cancer , Jg. 148 2021, Nr. 7, S. 1695 – 1707DOI (Open Access)
-
Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practiceIn: Journal of Neuro-Oncology , Jg. 148 2020, Nr. 3, S. 489 – 500DOI (Open Access)
-
Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastomaIn: Cancer Medicine , Jg. 6 2017, Nr. 1, S. 89 – 99DOI (Open Access)
-
Bevacizumab Plus irinotecan versus temozolomide in newly diagnosed O⁶-methylguanine-DNA methyltransferase nonmethylated glioblastoma : The randomized GLARIUS trialIn: Journal of Clinical Oncology (JCO) , Jg. 34 2016, Nr. 14, S. 1611 – 1619
-
Late Pseudoprogression in Glioblastoma : Diagnostic Value of Dynamic O-(2-[¹⁸ F]fluoroethyl)-L-Tyrosine PETIn: Clinical Cancer Research , Jg. 22 2016, Nr. 9, S. 2190 – 2196
-
Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphomaIn: Journal of Clinical Oncology (JCO) , Jg. 34 2016, Nr. 15, S. 1757 – 1763DOI (Open Access)
-
Prognostic factors in recurrent glioblastoma patients treated with bevacizumabIn: Journal of Neuro-Oncology , Jg. 129 2016, Nr. 1, S. 93 – 100
-
Sarcomeric lesions and remodeling proximal to intercalated disks in overload-induced cardiac hypertrophyIn: Experimental Cell Research , Jg. 348 2016, Nr. 1, S. 95 – 105
-
The earlier the better? : Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastomaIn: Journal of Cancer Research and Clinical Oncology , Jg. 142 2016, Nr. 8, S. 1825 – 1829
-
Tlr2 deficiency does not limit the development of left ventricular hypertrophy in a model of transverse aortic constriction induced pressure overloadIn: Journal of Negative Results in BioMedicine , Jg. 15 2016, Nr. 1, 9DOI (Open Access)
-
¹⁸F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumorIn: Oncology Letters , Jg. 12 2016, Nr. 6, S. 4705 – 4707DOI (Open Access)
-
¹⁸F–fluoroethyl–L–tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case reportIn: Oncology Letters , Jg. 11 2016, Nr. 3, S. 2195 – 2198DOI (Open Access)
-
Tlr4 deficiency protects against cardiac pressure overload induced hyperinflammationIn: PLoS ONE , Jg. 10 2015, Nr. 11, e0142921DOI (Open Access)
-
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant gliomaIn: Oncology , Jg. 86 2014, Nr. 5-6, S. 369 – 372
-
FLAIR-Only progression in bevacizumab-treated relapsing glioblastoma does not predict short survivalIn: Oncology , Jg. 85 2013, Nr. 3, S. 191 – 195
-
In vivo differentiation of human periodontal ligament cells leads to formation of dental hard tissueIn: Journal of Orofacial Orthopedics , Jg. 74 2013, Nr. 6, S. 494 – 505
-
TLR2 stimulation induces cardiac inflammation but not cardiac depression in vivoIn: Journal of Inflammation , Jg. 10 2013, Nr. 1, 33DOI (Open Access)
-
Vemurafenib for leptomeningeal melanomatosisIn: Journal of Clinical Oncology (JCO) , Jg. 31 2013, Nr. 11
-
Effect of intermittent PTH(1-34) on human periodontal ligament cells transplanted into immunocompromised miceIn: Tissue Engineering / Part A , Jg. 18 2012, Nr. 17-18, S. 1849 – 1856DOI (Open Access)
-
AI Based Prediction of Clinical TTFields Response in Glioblastoma Patients (Retrospective Analysis)
29th Annual Meeting and Education Day of the Society-for-Neuro-Oncology (SNO): NOV 21-24, 2024; Houston, USA,In: Neuro-Oncology , Jg. 26 2024, Nr. Suppl. 8: Abstracts from the 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, S. viii112 – viii112 -
Decoding glioblastoma survival : Unraveling the prognostic potential of olfactory function in a prospective observational study
29th Annual Meeting and Education Day of the Society-for-Neuro-Oncology (SNO): NOV 21-24, 2024; Houston, USA,In: Neuro-Oncology , Jg. 26 2024, Nr. Suppl. 8: Abstracts from the 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, S. viii95 – viii95 -
Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase I/II GLORIA trial
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology , Jg. 35 2024, Nr. Suppl. 2, S. S408 -
68Ga-NeoB PET for Glioma and Breast Cancer : First Results from a Prospective Observational Trial
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 50 2023, Nr. 1 supplement, S. S265 -
Decoding glioblastoma survival : unraveling the prognostic potential of olfactory function in a prospective observational study
28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO); NOV 15-19, 2023; Vancouver, Canada,In: Neuro-Oncology , Jg. 25 2023, Nr. Suppl. 5, S. v92 – v92 -
Fet pet sensitivity in primary brain tumors according to cns who 2021 : value and pitfalls in presurgical implementationIn: Neuro-Oncology , Jg. 25 2023, Nr. Suppl. 5, S. v204 – v205
-
Immunogenicity of an additional dose of covid-19 vaccine in fully vaccinated patients with glioma to evaluate new national vaccination guidelines : a prospective cohort studyIn: Neuro-Oncology , Jg. 25 2023, Nr. Suppl. 5, S. v63 – v64
-
Interim data on dual inhibition of post-radiogenic angio-vasculogenesis by olaptesed pegol (nox-a12) and bevacizumab in glioblastoma from the first expansion arm of the phase 1/2 gloria trial
28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO); NOV 15-19, 2023; Vancouver, Canada,In: Neuro-Oncology , Jg. 25 2023, Nr. Suppl. 5, S. v90 – v91 -
Investigating safety and efficacy of ttfields prior and concomitant to radiotherapy in newly diagnosed glioblastoma : First results of the pricottf phase I/II trial
28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO); NOV 15-19, 2023; Vancouver, Canada,In: Neuro-Oncology , Jg. 25 2023, Nr. Suppl. 5, S. v91 – v92 -
Predicting and targeting clonally expanding, tmz-resistant tumor cells in glioblastoma
28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO); NOV 15-19, 2023; Vancouver, Canada,In: Neuro-Oncology , Jg. 25 2023, Nr. Suppl. 5, S. v110 – v110 -
Safety and efcacy of TTFields therapy prior and concomitant to radiotherapy in newly diagnosed glioblastoma : the PriCoTTF phase I/II trialIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 199 2023, Nr. Suppl. 1, S. S32DOI (Open Access)
-
Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology , Jg. 34 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S395 -
Temporal muscle thickness as a prognostic marker in a real-life cohort of newly diagnosed MGMT promoter methylated glioblastoma patients : a multicentric imaging analysisIn: Neuro-Oncology , Jg. 25 2023, Nr. Suppl. 5, S. v192 – v193
-
PriCoTTF Trial : A Phase I//II Trial of TTFields Prior and Concomitant to Radiotherapy in newly diagnosed Glioblastoma
2021 Society for Neuro-Oncology’s 26th Annual Scientific Meeting and Education Day,In: Neuro-Oncology , Jg. 23 2021, Nr. Supplement_6, S. vi68 – vi68DOI (Open Access)